SCHEMBL10314573

SCHEMBL10314573

Cn1c(=O)c2c(OCC3CCCO3)c(C=O)sc2c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ALDH1A1 P00352 8/20 0.42
▸ HSD17B10 Q99714 5/20 0.42
▸ HPGD P15428 4/20 0.42
▸ HTT P42858 2/20 0.42
▸ TSHR P16473 3/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ ATM Q13315 1/20 0.38
▸ THRB P10828 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SCD O00767 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1062762 0.84 KDM4E (0.48) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1061751 0.82 KDM4E (0.50) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1062258 0.81 HSD17B10 (0.48) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1061214 0.81 KDM4E (0.60) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1062606 0.81 KDM4E (0.45) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1062598 0.81 KDM4E (0.45) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL10314419 0.80 KDM4E (0.44) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1061867 0.80 KDM4E (0.44) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1058581 0.79 KDM4E (0.43) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL1061099 0.79 KDM4E (0.44) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM4E 528/4885SMN1; SMN2 3564/4885KMT2A 453/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM4E 464/4885SMN1; SMN2 3559/4885KMT2A 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback